Abstract
In the adult group, 66% of patients were at INTERMACS level 1, critical cardiogenic shock, and 19% were at level 2, progressive decline. Indications for primary MCS included: acute exacerbation of chronic heart failure, acute cardiogenic shock and respiratory failure. Altogether, procedural success was accomplished in 49.4% of patients. MCS efficiently bridged 14 patients with heart failure to heart transplantation. In 15 patients, long term support was instituted, either as a destination therapy or as a bridge to heart transplant; 13 received HeartMate II, and 2 patients received HeartWare. One patient with respiratory failure was successfully bridged to lung transplantation. In the pediatric group, 60% patients were bridged to recovery. Postcardiotomy MCS was used in 33.7% patients. Patient outcome after 30 days was assessed as: alive (22.4%), alive on support (13.5%), dead (64.0%). The most common perioperative complication was renal failure, in 42.7% patients.
Highlights
Treatment of end-stage heart failure has markedly evolved
We report our experience in mechanical circulatory support (MCS) program since 2008
Short, intermediate and long term MCS can be instituted for different clinical indications, ranging from postcardiotomy circulatory failure, acute cardiogenic or respiratory shock, chronic heart failure in patients not eligible for a transplant to heart transplant function deterioration
Summary
Treatment of end-stage heart failure has markedly evolved. With only a limited number of available heart transplants (24 in 2012) in our institution, mechanical circulatory support (MCS) has become an integral part of acute and end-stage heart failure treatment and has improved survival. Optimal utilization of mechanical circulatory support and transplant resources in the comprehensive treatment of terminal heart failure From 23rd World Congress of the World Society of Cardio-Thoracic Surgeons Split, Croatia. Background Treatment of end-stage heart failure has markedly evolved.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
